Opioid-induced androgen deficiency

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 3, 2006, Pages 262-266

  Daniell, Harry W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

DHEAS deficiency; Gonadotropins; Opioids; Testosterone deficiency; Testosterone therapy

Indexed keywords

DIAMORPHINE; METHADONE; OPIATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANEMIA; CHRONIC PAIN; CLINICAL FEATURE; DEPRESSION; DRUG DEPENDENCE; DRUG INDUCED DISEASE; ERECTILE DYSFUNCTION; FATIGUE; HABITUATION; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADOTROPIC HYPOGONADISM; LIBIDO DISORDER; OSTEOPOROSIS; PATHOPHYSIOLOGY; PSYCHOSOCIAL DISORDER; REVIEW; SYMPTOMATOLOGY; VASOMOTOR DISORDER;

EID: 33646714429     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000224806.08824.dc     Document Type: Review

References (45)

1. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3:377-384.
2. Facchinetti F, Volpe A, Farci G, et al. hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend 1985; 15:361-366.
3. Palm S, Moenig H, Maier C. Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis. Methods Find Exp Clin Pharmacol 1997; 19:269-273.
4. Woody G, McLellan AT, O'Brien C, et al. Hormone secretion in methadone-dependent and abstinent patients. NIDA Res Monogr 1988; 81:216-223.
5. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85:2215-2222.
6. Roberts LJ, Finch PM, Pullan PT, et al. Sex hormone suppression by intrathecal opioids:a prospective study. Clin J Pain 2002; 18:144-148.
7. Finch PM, Roberts LJ, Price L, et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000; 16:251-254.
8. Paice J, Penn R, Ryan W. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage 1994; 9:126-131.
9. Rajagopal A, Vassilopoulou-Sellin R, Palmer J, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004; 100:851-858.
10. Daniell HW, Mazer NA, Lentz R. Open-Label pilot study of testosterone patch therapy in men. J Pain 2006; 7:200-210.
11. Daniell HW, Lentz R, Mazer NA. Testosterone patch therapy increases sex hormone levels with associated improvements in sexual function, mood, and hematocrit in men with opioid induced androgen deficiency (OPIAD) [abstract]. Pharmacotherapy 2004; 24 (Suppl 10):Abstract 15E.
12. Mazer N, Chapman C, Daniell H, et al. Opioid induced androgen deficiency in men (OPIAD): an estimate of the potential patient population in the U.S. and Canada [abstract] J Pain 2004; 5:S73.
13. Giri M, Kaufman JM. Opioidergic modulation of in vitro pulsatile gonadotropin-releasing hormone release from the isolated medial basal hypothalamus of the male guinea pig. Endocrinology 1994; 135:2137-2143.
14. Faletti A, Mastronardi C, Lomniczi A, et al. β-Endorphin blocks luteinizing hormone-releasing hormone release by inhibiting the nitricoxidergic pathway controlling its release. Proc Natl Acad Sci U S A 1999; 96:1722-1726.
15. Blank MS, Fabbri A, Catt KJ, et al. Inhibition of luteinizing hormone relase by morphine an endogenous opiates in cultured pituitary cells. Endocrinology 1986; 118:2097-2101.
16. Adams ML, Sewing B, Forman JB, et al. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther 1993; 266:323-328.
17. Ibanez L, Potau N, Marco MV, et al. Corticotropin-releasing hormone: a potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche. J Clin Endocrinol Metab 1999; 84:4602-4606.
18. Allolio B, Schulte HM, Deusb U, et al. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol (Copenh) 1987; 114:509-514.
19. Palm S, Moenig H, Maier C. Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis. Methods Find Exp Clin Pharmacol 1997; 19:269-273.
20. Facchinetti F, Comitini G, Petraglia F, et al. Reduced estriol and dehydroepiandrosterone sulphate plasma levels in methadone-addicted pregnant women. Eur J Obstet Gynecol Reprod Biol 1986; 23:67-73.
21. Santen FJ, Sofsky J, Bilic N, et al. Mechanism of action of narcotics in the production of menstrual dysfunction in women. Fertil Steril 1975; 26:538-548.
22. Schmittner J, Schroeder JR, Epstein DH, et al. Menstrual cycle length during methadone maintenance. Addiction 2005; 100:829-836.
23. Svartberg J, Midtby M, Bonaa KH, et al. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol 2003; 149:145-152.
24. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996; 81:1821-1826.
25. Wang C, Chan V, Yeung RT. The effect of heroin addiction on pituitary-testicular function. Clin Endocrinol (Oxf) 1978; 9:455-461.
26. Daniell HW. Opioid Osteoporosis. Arch Intern Med 2004; 164:338.
27. th Annual Meeting; 16-19 June; New Orleans. Chevy Chase: The Endocrine Society; 2004. Abstract P3-599.
28. Shorr RI, Griffin MR, Dougherty JR, et al. Opioid analgesics and the risk of hip fractures in the elderly: codeine and propoxyphene. J Gerontol 1992; 47:M111-M115.
29. Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998; 148:887-892.
30. Ensrud K, Blackwell T, Mangione C, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163:949-957.
31. Pedrazzoni M, Vescovi PP, Maninetti L, et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) 1993; 129:42-45.
32. Wilczek H, Stepan J. Bone metabolism in individuals dependent on heroin and after methadone administration. Cas Lek Cesk 2003; 142:606-608.
33. Rico H, Costales C, Cabranes JA, et al. Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery. Obstet Gynecol 1990; 75:998-1000.
34. Perez-Castrillon JL, Olmos JM, Gomez JJ, et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 2000; 72:187-194.
35. Daniell HW. Higher erythropoietin requirements in hypogonadal and iron-deficient men on hemodialysis. Dial Transplant 2005; 34:326-336.
36. Kalra PS, Sahu A, Kalra SP. Opiate-induced hypersensitivity to testosterone feedback: pituitary involvement. Endocrinology 1988; 122:2872.
37. Gabriel SM, Berglund LA, Simpkins JW. Chronic morphine treatment enhances the negative and positive feedback effects of estradiol on gonadotropin secretion in ovariectomized rats. Endocrinology 1987; 120:1799-1805.
38. Hall GM, Lacoumenta S, Hart GR, et al. Site of action of fentanyl in inhibiting the pituitary-adrenal response to surgery in man. Br J Anaesth 1990; 65:251-253.
39. Raff H, Norton A, Flemma R, et al. Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl. J Clin Endocrinol Metab 1987; 65:295.
40. Forman LJ, Tingle V, Estilow S, et al. The response to analgesia testing is affected by gonadal steroids in the rat. Life Sci 1989; 45:447-454.
41. Pednekar JR, Mulgaonker VK. Role of testosterone on pain threshold in rats. Indian J Physiol Pharmacol 1995; 39:423-424.
42. Frye CA, Seliga AM. Testosterone increases analgesia, anxiolysis, and cognitive performance of male rats. Cogn Affect Behav Neurosci 2001; 1:371-381.
43. Reddy DS, Kulkarni SK. Chronic neurosteroid treatment prevents the development of morphine tolerance and attenuates abstinence behavior in mice. Eur J Pharmacol 1997; 15:19-25.
44. Ren X, Noda Y, Mamiya T, et al. A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase. Behav. Brain Res 2004; 152:243-250.
45. Budziszewska B, Jaworska-Feil L, Lason W. Neurosteroids and the naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur Neuropsychopharmacol 1996; 6:135-140.